ADULT USE CANNABIS REVENUE INCREASES 27% FROM PRIOR QUARTER AND FIFTH CONSECUTIVE QUARTER OF POSITIVE ADJUSTED EBITDA

Net Revenue Increases 5% from Prior Quarter and 18% from Prior Year Quarter
Adjusted EBITDA from Cannabis Operations of $9.3 Million Increased 55% from Prior Quarter
Cash Cost Per Gram Remained Below $1 and Decreased 5% from Prior Quarter to $0.88

LEAMINGTON, ON, July 29, 2020 – Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA) (Nasdaq: APHA), a leading global cannabis company, today reported its financial results for the fourth quarter and fiscal year ended May 31, 2020. All amounts are expressed in Canadian dollars, unless otherwise noted and except for per gram, kilogram, kilogram equivalents, and per share amounts.


  Subscribe to news from
Aphria

Be the first to know when breaking news are released.



“At Aphria, we are setting ourselves apart from the rest of the cannabis industry,” said Irwin D. Simon, Chairman and Chief Executive Officer. “We have generated some of the strongest sales growth, we have one of the strongest balance sheets and cash positions, compelling consumer brands and a well-diversified global business. We are grateful for the dedication of our employees for whom our commitment to protect their safety is unwavering and remains a founding principle of our company. Our strong finish to fiscal year 2020 demonstrates that this was a transformative year for Aphria, as our net revenue increased 129% from fiscal year 2019. We continue to focus on capturing strong market share in Canada by executing upon our strategic plan and positioning Aphria as a leader in category innovation. With exciting new product categories and line extensions launching in the very near future, we believe our award-winning adult-use portfolio remains unmatched in the industry. By building on this foundation, we remain focused on the highest return opportunities for growth and long-term value creation.”

Key Operating Highlights – Fourth Quarter Fiscal 2020

  • Gross revenue for adult-use cannabis of $56.7 million in the fourth quarter, an increase of 27% from prior quarter and the fifth consecutive quarter of growth.
  • Net cannabis revenue of $53.1 million in the fourth quarter, an increase of 81% from prior year quarter.
  • Net revenue of $152.2 million in the fourth quarter, an increase of 18% from prior year quarter and increase of 5% from prior quarter.
  • Cash cost to produce dried cannabis per gram of $0.88 in the fourth quarter, a decrease of 5% from prior quarter.
  • Adjusted EBITDA of $8.6 million in the fourth quarter, an increase of 49% from the prior quarter.
  • Adjusted EBITDA from cannabis operations of $9.3 million in the fourth quarter, an increase of 55% from the prior quarter.
  • Ended fourth quarter with a strong balance sheet and liquidity, including $497.2 million of cash and cash equivalents to fund planned Canadian and International growth.
  • Received its European Union Good Manufacturing Practices (“EU GMP”) certification from the Malta Medicines Authority (“MMA”) at the Company’s subsidiary, ASG Pharma Ltd., providing the Company with the ability to ship finished dried flower and finished oil for medicinal and research use in permitted jurisdictions throughout the European Union and strengthening the Company’s leadership in the region.
  • Liquidated $39 million Promissory Note from GA Opportunities Corp. for proceeds of approximately $26 million.
  • Reduced debt and eliminated $6.7 million in annual cash interest costs by repurchasing an aggregate of approximately $127.5 million convertible senior notes at a 25% discount to their face value, using shares issued at a 31% premium to Aphria’s closing market price as of May 7, 2020.
  • Recorded a non-cash impairment of $64.0 million in the fourth quarter, which is largely attributable to measures taken with respect to certain of the Company’s international businesses in response to the COVID-19 pandemic.
  • Recognized for Executive Gender Diversity by Globe and Mail’s inaugural Report on Business Women Lead Here list, an annual benchmark of executive gender diversity in corporate Canada.

Key Operating Highlights – Fiscal Year 2020

  • Gross revenue for adult-use cannabis of $150.4 million in 2020, an increase of 307% from 2019.
  • Gross cannabis revenue of $204.7 million in 2020, an increase of 129% from $89.4 million in 2019.
  • Net revenue of $543.3 million in 2020, an increase of 129% from $237.1 million in 2019.
  • Cash cost to produce dried cannabis per gram of $1.04 in 2020, a decrease of 24.1% from 2019.
  • Positive Adjusted EBITDA of $17.2 million in 2020, compared to a loss of $27.7 million in 2019.
  • Adjusted EBITDA from cannabis operations of $20.1 million in 2020, compared to a loss of $17.5 million in 2019.

Subsequent Events

  • Aphria transferred its stock exchange listing from the New York Stock Exchange to The Nasdaq Global Select Market (“Nasdaq”) on June 8, 2020. This transition did not impact the Company’s primary listing on the Toronto Stock Exchange (TSX: APHA).
  • Aphria, Emblem Cannabis Corporation (“Emblem”), and Aleafia Health Inc. (TSX: AH, OTC: ALEAF) amicably settled their outstanding dispute related to the termination of the parties’ wholesale cannabis supply agreement on June 25, 2020, ending any and all potential claims and litigation against and between Aphria, Emblem, and Aleafia Health relating to the supply agreement.
  • Filed Prospectus supplement for $100 million (USD) At-the-Market program.

Key Financial Highlights
(In thousands of Canadian dollars)








Three months ended

Three months ended 


Twelve months ended

Twelve months ended


May 31, 2020

May 31, 2019


May 31, 2020

May 31, 2019

Net revenue

$152,203

$128,568


$543,339

$237,110

Gross profit

$47,390

$36,007


$191,975

$75,421

Adjusted cannabis gross profit 1

$28,079

$15,165


$87,233

$40,596

Adjusted cannabis gross margin 1

52.9%

53.0%


50.1%

53.3%

Adjusted distribution gross profit 1

$11,947

$12,274


$46,526

$19,805

Adjusted distribution gross margin 1

12.1%

12.4%


12.6%

12.5%

Net income (loss)

($98,843)

$15,760


($84,634)

($16,499)

Adjusted EBITDA 1

$8,558

$209


$17,232

($27,720)














Q4-2020

Q3-2020




Distribution revenue

$99,137

$88,308




Net cannabis revenue

$53,066

$55,566




Net revenue

$152,203

$144,424




Kilograms (or kilogram equivalents) sold 1

12,557

14,014




Cash cost to produce dried cannabis / gram1

$0.88

$0.93




“All-in” cost of goods sold / gram1

$1.69

$1.69




Adjusted EBITDA from cannabis operations 1

$9,360

$6,031




Adjusted EBITDA from businesses under development 1

($2,745)

($2,859)




Adjusted EBITDA from distribution operations 1

$1,943

$2,564




Cash and cash equivalents & marketable securities

$497,222

$515,102




Working capital

$732,908

$746,572




Capital and intangible asset expenditures -wholly-owned subsidiaries1 

$25,569

$23,839




Source: Aphria Inc. May 31, 2020 MD&A1

___________________

1

In this press release, reference is made to adjusted cannabis gross profit, adjusted cannabis gross margin, adjusted distribution gross profit, adjusted distribution gross margin, adjusted EBITDA, adjusted EBITDA from cannabis operations, adjusted EBITDA from distribution operations, adjusted EBITDA from businesses under development, gram equivalents, cash costs to produce dried cannabis per gram, “all-in” cost of sales of dried cannabis per gram and capital and intangible asset expenditures – wholly-owned subsidiaries, which are not measures of financial performance under International Financial Reporting Standards (IFRS). These metrics and measures are not recognized measures under IFRS, do not have meanings prescribed under IFRS and are as a result unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complimentary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company’s Management’s Discussion and Analysis for the year ended May 31, 2020, filed on SEDAR and EDGAR.

Net revenue for the three months ended May 31, 2020 was $152.2 million, an increase of 18% from $128.6 million in the same period last year. Fourth quarter fiscal year 2020 net revenue was 5% higher when compared to the prior quarter net revenue of $144.4 million, due to increases in net distribution revenue and net cannabis revenue. Net revenue included 10,831 kilogram equivalents sold for the adult-use market, 1,273 kilogram equivalents for medical cannabis sales and 453 kilogram equivalents sold in the wholesale market.

The average retail selling price of medical cannabis (exclusive of wholesale), before excise tax, increased to $6.63 per gram in the quarter, compared to $6.41 in the prior quarter. The average selling price of adult-use cannabis, before excise tax, decreased to $5.23 per gram in the quarter, compared to $5.47 per gram in the prior quarter, primarily as a result of a change in sales mix and price reductions in key markets to solidify market share.

Adjusted cannabis gross profit for the fourth quarter was $28.1 million, with an adjusted cannabis gross margin of 52.9%, compared to $23.7 million and 42.7% in the prior quarter. The increase in adjusted cannabis gross margin was primarily due to the increase in the higher margin adult-use sales to wholesale transaction ratio in the current quarter, and higher usage of the lower-cost cannabis produced by Aphria versus purchased cannabis.

Adjusted distribution gross profit for the fourth quarter was $11.9 million, with an adjusted distribution gross margin of 12.1%, compared to $11.4 million and 12.9% in the prior quarter. The decrease in adjusted distribution gross margin was primarily related to the impacts of COVID-19 on sales mix.

Selling, general, and administrative costs in the quarter increased to $116.6 million from $50.9 million in the prior quarter and $60.0 million in the prior year. The increase was mainly related to $64.0 million of impairment charges recorded in the fourth quarter, which is largely attributable to the COVID-19 pandemic measures taken with respect to certain of the Company’s international businesses in response to the COVID-19 pandemic, whereas none was recorded in the prior quarter or the same quarter of the prior year.

Net loss for the fourth quarter of fiscal year 2020 was $98.8 million, or a loss of $0.39 per share, compared to net income of $5.7 million, or $0.02 per share in the prior quarter, and net income of $15.8 million, or $0.05 per share for the same period last year. The decrease in net income was a result of the non-cash impairment recognized in the fourth quarter as mentioned above as well as non-operating losses mainly driven by changes in fair value of long-term investments and convertible debentures, resulting from a decline in the trading prices of the securities of participants in the cannabis market.

Adjusted EBITDA increased by $2.8 million to $8.6 million for the fourth quarter compared to $5.7 million in the prior quarter. Adjusted EBITDA from cannabis operations for the fourth quarter was $9.3 million compared to $6.0 million in the prior quarter. The adjusted EBITDA loss from businesses under development for the fourth quarter was $2.7 million compared to a loss of $2.9 million in the prior quarter. Adjusted EBITDA from distribution operations for the fourth quarter was $1.9 million, compared to $2.6 million the prior quarter.

The Company ended the fourth quarter with a strong balance sheet, including $497.2 million of cash and cash equivalents.

ATM (“At-the-Market”) Program Established

The Company also announced today that it has established an at-the-market equity program (the “ATM Program“) under which the Company may from time to time sell an aggregate of up to US$100,000,000 (or its Canadian dollar equivalent) of its common shares (“Common Shares“) through the Agents (as defined below). Any Common Shares sales under the ATM Program will be made through “at-the-market distributions” as defined in National Instrument 44-102 and sold through the Toronto Stock Exchange (the “TSX“), the NASDAQ Global Select Market (the “NASDAQ“) or any other marketplace on which the Common Shares are listed, quoted or otherwise traded, at the prevailing market price at the time of sale. Sales may also be made in privately negotiated transactions.

The ATM Program will be effective until the earlier of December 22, 2021 and the issuance and sale of all of the Common Shares issuable pursuant to the ATM Program, unless terminated prior to such date by the Company or the Agents. Aphria intends to use the net proceeds from the ATM Program, if any, to fund Canadian and international expansion, working capital and general corporate purposes or to repay indebtedness. As Common Shares distributed in the ATM Program will be issued and sold at the prevailing market price at the time of the sale, or in privately negotiated transactions, prices may vary among purchasers during the period of the distribution.

Distributions of the Common Shares through the ATM Program will be made pursuant to the terms of an equity distribution agreement dated July 29, 2020 among the Company, Jefferies LLC and Canaccord Genuity LLC, as U.S. agents and Canaccord Genuity Corp. and Jefferies Securities, Inc., as Canadian agents (collectively, the “Agents“).

The offering under the ATM Program will be made only pursuant to a prospectus supplement dated July 29, 2020 (the “Prospectus Supplement“) to the Company’s Canadian base shelf prospectus (the “Shelf Prospectus“) dated November 22, 2019, and pursuant to a prospectus supplement dated July 29, 2020 (the “U.S. Prospectus Supplement“) to the Company’s U.S. base prospectus (the “U.S. Base Prospectus“) dated November 22, 2019 and included in its registration statement on Form F-10, as amended (the “Registration Statement“) (File No. 333-233426). The Registration Statement was declared effective by the United States Securities and Exchange Commission (the “SEC“) on November 26, 2019. The Prospectus Supplement and the Shelf Prospectus are available on the SEDAR website maintained by the Canadian Securities Administrators at www.sedar.com, and the U.S. Prospectus Supplement, the U.S. Base Prospectus and the Registration Statement are available on EDGAR at the SEC’s website at www.sec.gov. Alternatively, the agents will send copies of the Prospectus Supplement and the Shelf Prospectus, or the U.S. Prospectus Supplement and the U.S. Base Prospectus, as applicable, upon request by contacting in the U.S.: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at (877) 821-7388, or by e-mail at [email protected] or Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, Suite 1200, Boston, MA 02110, Attn: Equity Syndicate Department, by telephone at (617) 371-3900 or by e-mail at [email protected]; or in Canada: Canaccord Genuity Corp., 161 Bay Street, Suite 3000, P.O. Box 516, Toronto, ON Canada M5J 2S1, Attention: Syndication, phone: 1-416-869-7368, email: [email protected] or Jefferies Securities, Inc., 161 Bay Street, Suite 2700, Toronto, ON Canada M5J 2S1, Attention: Steven Latimer, phone: 416-572-2215.

This news release does not constitute an offer to sell or the solicitation of an offer to buy the Common Shares, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Conference Call

Aphria executives will host a conference call to discuss these results today at 9:00 am Eastern Time. To listen to the live call, dial (888) 231-8191 from Canada and the U.S. or (647) 427-7450 from International locations and use the passcode 3439698. A telephone replay will be available approximately two hours after the call concludes through August 29, 2020. To access the recording dial 1-855-859-2056 and use the passcode 3439698.

There will also be a simultaneous, live webcast available on the Investors section of Aphria’s website at aphriainc.com. The webcast will be archived for 30 days.

We Have A Good Thing Growing

About Aphria Inc.

Aphria Inc. is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion.

For more information, visit: aphriainc.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking information or forward-looking statements (together, “forward-looking statements”) under applicable securities laws and are expressly qualified by this cautionary statement. Any information or statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements, including, but not limited to, statements in this news release with regards to the anticipating timing for the release of new product offerings, Aphria’s market position, ability to generate consistent growth, and net revenue and adjusted EBITDA. The Company uses words such as “forecast”, “future”, “should”, “could”, “enable”, “potential”, “contemplate”, “believe”, “anticipate”, “estimate”, “plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative of these terms or similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Various assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this news release. Forward-looking statements reflect management’s current beliefs with respect to future events and are based on information currently available to management including based on reasonable assumptions, estimates, internal and external analysis and opinions of management considering its experience, perception of trends, current conditions and expected developments as well as other factors that management believes to be relevant as at the date such statements are made. Forward-looking statements involve significant known and unknown risks and uncertainties. Many factors could cause actual results, performance or achievement to be materially different from any future forward-looking statements. Factors that may cause such differences include, but are not limited to, risks associated with COVID-19 nationally and globally which could have a material adverse impact on Aphria’s business, operations and financial results, including disruptions in cultivation and processing, supply chains and sales channels, as well as a deterioration of general economic conditions including national and/or global recessions and the response of governments to the COVID-19 pandemic in respect of the operation of retail stores; general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis or otherwise affecting Aphria’s business or its consumers generally; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the cannabis industry in Canada generally; income tax and regulatory matters, including delays in the issuance of licenses; the sale and distribution of vapes; the ability of Aphria to meet its liquidity requirements to fund ongoing operations; the ability of Aphria to implement its business strategies; competition; crop failure; safety of derivative cannabis products; currency and interest rate fluctuations.

Readers are cautioned that the foregoing list is not exhaustive and should consider as other factors discussed under the heading “Risk Factors” in Aphria’s most recent Annual Information Form and under the heading “Industry Trends and Risks” in Aphria’s Management’s Discussion and Analysis for the three and twelve months ended May 31, 2020, each available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws. Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

The schedule below is an excerpt of Aphria Inc.’s financial statements prepared on a basis consistent with IFRS for the three and twelve months ended on May 31, 2020 and filed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. This schedule does not contain all of the information in Aphria Inc.’s financial statements that is important to you. You should read the financial statements and Management’s Discussion and Analysis carefully to obtain a comprehensive understanding of Aphria Inc.’s financial statements and notes thereto under IFRS and related information.

Aphria Inc.
Consolidated Statements of Income and Comprehensive Income
(In thousands of Canadian dollars, except share and per share amounts)







 For the year ended
May 31, 







Note

2020

2019

Cannabis revenue




$  204,736

$  89,383

Distribution revenue




369,214

157,931

Insurance recovery




1,000

Excise taxes




(31,611)

(10,204)










Net revenue




543,339

237,110










Production costs



5

64,972

36,446

Cost of cannabis purchased




21,920

Cost of goods purchased




322,688

138,126










Gross profit before fair value adjustments




133,759

62,538










Fair value adjustment on sale of inventory



5

57,039

27,724

Fair value adjustment on growth of biological assets



6

(115,255)

(40,607)










Gross profit




191,975

75,421

Operating expenses:






General and administrative



23

99,977

69,752

Share-based compensation




24

22,500

26,080

Amortization




21,747

14,084

Selling




21,042

4,961

Marketing and promotion




20,464

23,010

Research and development




2,568

1,391

Impairment



10

63,971

58,039

Transaction costs




5,763

23,259








258,032

220,576










Operating loss




(66,057)

(145,155)










Finance income (expense), net



25

(26,347)

6,575

Non-operating income, net 



26

11,687

122,935

Loss before income taxes




(80,717)

(15,645)










Income taxes (recovery)



15

3,917

854

Net loss




(84,634)

(16,499)










Other comprehensive loss






Other comprehensive loss




(1,150)

(119)

Comprehensive loss




$  (85,784)

$  (16,618)










Total comprehensive income (loss) attributable to:





Shareholders of Aphria Inc.




(91,961)

(14,667)

Non-controlling interests



22

6,177

(1,951)








$  (85,784)

$  (16,618)










Weighted average number of common shares – basic




257,914,589

242,763,558

Weighted average number of common shares – diluted




257,914,589

242,763,558










Loss per share – basic



28

$  (0.33)

$  (0.07)

Loss per share – diluted



28

$  (0.33)

$  (0.07)

Aphria Inc.
Consolidated Statements of Income and Comprehensive Income
(In thousands of Canadian dollars, except share and per share amounts)







 For the three months
May 31, 








2020

2019

Cannabis revenue





$  65,461

$  34,306

Distribution revenue





99,137

99,186

Excise taxes





(12,395)

(4,924)










Net revenue





152,203

128,568










Production costs





18,917

13,113

Cost of cannabis purchased




6,070

Cost of goods purchased





87,190

87,270










Gross profit before fair value adjustments



40,026

28,185










Fair value adjustment on sale of inventory



20,979

9,649

Fair value adjustment on growth of biological assets



(28,343)

(17,471)










Gross profit





47,390

36,007

Operating expenses:







General and administrative




27,676

26,191

Share-based compensation




4,855

3,084

Amortization





5,491

4,528

Selling





8,311

2,949

Marketing and promotion





3,853

2,625

Research and development



576

294

Impairment





63,971

Transaction costs





1,859

20,329








116,592

60,000










Operating loss





(69,202)

(23,993)










Finance income (expense), net




(8,732)

(2,918)

Non-operating income, net 




(23,032)

43,124










Loss before income taxes





(100,966)

16,213










Income taxes (recovery)





(2,123)

453

Net loss





(98,843)

15,760










Other comprehensive loss






Other comprehensive loss




1,580

(58)

Comprehensive loss





$  (97,263)

$  15,702










Total comprehensive income (loss) attributable to:




Shareholders of Aphria Inc.




(104,904)

16,862

Non-controlling interests





7,641

(1,160)








$  (97,263)

$  15,702

Aphria Inc.
Consolidated Statements of Financial Position
(In thousands of Canadian dollars)





Note

May 31,
2020

May 31,
2019

Assets




Current assets




Cash and cash equivalents


$  497,222

$  550,797

Marketable securities


20,199

Accounts receivable


55,796

25,488

Prepaids and other current assets

4

42,983

23,391

Inventory

5

264,321

91,529

Biological assets

6

28,341

18,725

Promissory notes receivable

14

39,200

Current portion of convertible notes receivable

11

14,626

11,500






903,289

780,829

Capital assets

8

587,163

503,898

Intangible assets

9

363,037

392,056

Convertible notes receivable

11

20,730

Interest in equity investees

12

9,311

Long-term investments

13

27,016

64,922

Goodwill

10

617,934

669,846






$  2,498,439

$  2,441,592

Liabilities




Current liabilities




Bank indebtedness

16

$  537

$  —

Accounts payable and accrued liabilities


152,750

105,813

Income taxes payable


6,410

2,722

Deferred revenue


902

23,678

Current portion of lease liabilities


1,315

Current portion of long-term debt

17

8,467

6,332






170,381

138,545

Long-term liabilities




Lease liabilities


5,828

Long-term debt

17

129,637

60,895

Convertible debentures

18

270,783

421,366

Deferred tax liability

15

83,468

87,633






660,097

708,439

Shareholders’ equity




Share capital

19

1,846,938

1,655,273

Warrants

20

360

1,336

Share-based payment reserve


27,721

36,151

Accumulated other comprehensive loss


(1,269)

(119)

Retained earnings (deficit)


(61,215)

12,103






1,812,535

1,704,744

Non-controlling interests

22

25,807

28,409






1,838,342

1,733,153






$  2,498,439

$  2,441,592


For the three months
ended May 31,

For the year ended
May 31,

2020

2019

2020

2019

Net income (loss)

$  (98,843)

$  15,760

$  (84,634)

$  (16,499)

Income taxes (recovery)

(2,123)

453

3,917

854

Finance (income) expense, net

8,732

2,918

26,347

(6,575)

Non-operating (income) loss, net

23,032

(43,124)

(11,687)

(122,935)

Amortization

14,439

8,611

49,271

22,940

Share-based compensation

4,855

3,084

22,500

26,080

Fair value adjustment on sale of inventory

20,979

9,649

57,039

27,724

Fair value adjustment on growth of biological assets

(28,343)

(17,471)

(115,255)

(40,607)

Impairment

63,971

63,971

58,039

Transaction costs

1,859

20,329

5,763

23,259

Adjusted EBITDA from businesses under development

2,745

5,514

13,385

16,240

Adjusted EBITDA from distribution operations

(1,943)

(3,872)

(10,511)

(6,036)

Adjusted EBITDA from cannabis operations

$  9,360

$  1,851

$  20,106

$  (17,516)














For the three months
ended May 31,

For the year ended
May 31,

2020

2019

2020

2019

Adjusted EBITDA from cannabis operations

$  9,360

$  1,851

$  20,106

$  (17,516)

Adjusted EBITDA from businesses under development

(2,745)

(5,514)

(13,385)

(16,240)

Adjusted EBITDA from distribution operations

1,943

3,872

10,511

6,036

Adjusted EBITDA

$  8,558

$  209

$  17,232

$  (27,720)

SOURCE Aphria Inc.

Aphria Inc. Announces Fourth Quarter and Fiscal Year 2020 Results

Related Links

http://aphria.com/